select between over 22,900 AI Tool and 17,900 AI News Posts.
The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain swelling and bleeding. It’s a major setback for the company as it competes with a similar treatment from Biogen (BIIB) and Eisai. Read more...